Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Ginkgo Bioworks Holdings

Shares in Ginkgo Bioworks jumped more than 7% in pre-market trading following the announcement of their collaboration with Merck & Co Inc (NYSE:MRK). The partnership aims to enhance biologics manufacturing.

Ginkgo Bioworks up 6% in pre-market after inking second Merck deal

Anixa Biosciences Inc

SAN JOSE, Calif. , Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the Company's breast cancer vaccine with Keytruda® (pembrolizumab).

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Ginkgo Bioworks Holdings Inc. shares DNA, were rising more than 5% in Monday's premarket trading after the company said it was collaborating with Merck & Co. Inc. MRK, -0.69% on improvements in biologic manufacturing. Ginkgo plans to use its abilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to boost yields and drive improvements in production efficiency.

Ginkgo Bioworks stock pops as company plans Merck collaboration

Selling a call spread out of the money in a sideways-to-downside formation has high probabilities of expiring worthless.

Merck Stock Today: Why A Bear Call Spread Places $111 In Your Pocket Today

The company posted upbeat Q2 results this week, with solid growth for Keytruda and Gardasil.

Should You Buy Merck Stock After An Upbeat Q2?

Honeywell

Verizon

Verizon is a debt-laden telecom giant that just got a bit of extra bad news. Merck is complicated and still looks expensive despite the stock pullback.

Is It Time to Buy the Dow Jones' 3 Worst-Performing July Stocks?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves Merck's ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older.

U.S. FDA Approves Merck's ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance.

Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View

Merck reported better-than-expected results and raised its sales outlook on rising drug and vaccine sales.

Merck Beats Quarterly Estimates, Lifts Outlook on Sales of Cancer Drug, HPV Shot

Merck & Co., Inc. (NYSE:MRK ) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ET Company Participants Peter Dannenbaum - VP, IR Robert Davis - Chairman & CEO Caroline Litchfield - CFO Dean Li - President, Merck Research Labs Conference Call Participants Geoff Meacham - Bank of America Mohit Bansal - Wells Fargo Louise Chen - Cantor Fitzgerald Seamus Fernandez - Guggenheim Akash Tewari - Jefferies Group Christopher Schott - JPMorgan Daina Graybosch - Leerink Partners Timothy Anderson - Wolfe Research Chris Shibutani - Goldman Sachs Andrew Baum - Citigroup Stephen Scala - TD Cowen Operator Thank you for standing by. Welcome to the Merck & Co. Q2 Sales and Earnings Conference Call.

Merck & Co., Inc. (MRK) Q2 2023 Earnings Call Transcript

Caterpillar

Stock markets looked poised to give back a little ground on the first day of August. Caterpillar reported solid growth in the second quarter, and shareholders expect more even in the face of macroeconomic challenges.

The 2 Dow Stocks Everyone's Watching Tuesday Morning

Merck & Co Inc (NYSE:MRK) saw strong sales during the second quarter for its cancer drug Keytruda and HPV vaccine Gardasil, leading the pharmaceutical company to raise its full-year guidance. Keytruda's sales rose by 19% from the previous year, reaching $6.27 billion, while Gardasil saw a significant 47% increase in quarterly sales, driven by higher demand in China.

Merck's Keytruda and Gardasil outperform expectations, boosting annual revenue forecast

Merck (MRK) came out with a quarterly loss of $2.06 per share versus the Zacks Consensus Estimate of a loss of $2.17. This compares to earnings of $1.87 per share a year ago.

Merck (MRK) Reports Q2 Loss, Tops Revenue Estimates

Merck & Co. Inc. MRK, +0.29% posted a narrower-than-expected loss for the second quarter early Tuesday following its acquisition of Prometheus Bio and sales that topped estimates, despite a steep decline in sales of its COVID treatment Lagevrio. The company swung to a net loss of $4.975 billion, or 2.35 a share, for the quarter, after income of $3.944 billion, or $1.55 a share, in the year-earlier period.

Merck posts narrower-than-expected loss and sales top estimates

Merck & Co posted narrower-than-expected second-quarter loss and raised its full-year profit forecast on Tuesday on the strength of its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.

Merck posts narrower-than-expected loss as sales of top drugs beat Street estimates

Prometheus Biosciences

Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.

Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

Merck topped second-quarter expectations Tuesday, though it reported a per-share loss. The news comes as Merck stock forms a flat base.

Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2023 Financial Results.

Merck Announces Second-Quarter 2023 Financial Results

AstraZeneca

Pfizer

Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare.

3 Pharma Stocks to Buy for Their Promising Progress

Apple

Cisco Systems

JPMorgan Chase & Co

Microsoft

NIKE

With the Dow Jones soaring on fading recession fears, its holdings are also becoming far more attractive, too. In fact, here are seven of the top Dow stocks to buy immediately.

7 Dow Stocks to Buy as Recession Fears Roll Back

Merck & Co Inc (NYSE:MRK)'s flagship breast cancer drug Keytruda met one of the primary goals of a late-stage clinical trial in breast cancer patients, the company announced Friday.  Taken in combination with chemotherapy, the drug was shown to help clear all signs of tumors compared to a placebo plus chemotherapy.

Merck's Keytruda gets encouraging study result ahead of earnings next week

Merck said on Friday its blockbuster drug Keytruda, in combination with chemotherapy, met one of the main goals in a late-stage trial testing it in some breast cancer patients.

Merck's Keytruda meets main goal in late-stage breast cancer study

BeiGene

Exelixis

Kura Oncology

Novartis

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer.

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Ligand's Collaborator Merck Announces V116 Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

News for Merck Stock (MRK)